TOP > 外国特許検索 > ANTI-MYRISTOYLATED PROTEIN ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, MYRISTOYLATED PROTEIN DETECTION KIT, DRUG, GENE, AND VECTOR

ANTI-MYRISTOYLATED PROTEIN ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, MYRISTOYLATED PROTEIN DETECTION KIT, DRUG, GENE, AND VECTOR

Foreign code F150008595
File No. (S2014-0380-N0)
Posted date 2015年11月26日
Country 世界知的所有権機関(WIPO)
International application number 2015JP057287
International publication number WO 2015137441
Date of international filing 平成27年3月12日(2015.3.12)
Date of international publication 平成27年9月17日(2015.9.17)
Priority data
  • 特願2014-052535 (2014.3.14) JP
Title ANTI-MYRISTOYLATED PROTEIN ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, MYRISTOYLATED PROTEIN DETECTION KIT, DRUG, GENE, AND VECTOR
Abstract Provided is an anti-myristoylated protein antibody or antigen-binding fragment thereof, characterized by having a light-chain variable domain consisting of CDR-L1 comprising the amino acid sequence shown by Sequence No. 1, CDR-L2 comprising the amino acid sequence shown by Sequence No. 2, and CDR-L3 comprising the amino acid sequence shown by Sequence No. 3, and/or a heavy-chain variable domain consisting of CDR-H1 comprising the amino acid sequence shown by Sequence No. 4, CDR-H2 comprising the amino acid sequence shown by Sequence No. 5, and CDR-H3 comprising the amino acid sequence shown by Sequence No. 6.
Outline of related art and contending technology BACKGROUND ART
Of the catalytic subunit of cAMP-dependent protein kinase by determining the primary sequence of the myristic acid is bonded to the N-terminus is discovered (see non-patent document 1.), Myristoylated proteins up to now reported 100 or more, a few percent of the total protein being under the myristoylation estimated from the genomic sequence (see non-patent document 2.).
And myristoylation, protein N-terminus having a carbon number of 14 saturated fatty acids and myristic acid is added which is a kind of post-translational modification, all this modification is ubiquitous in eukaryotic organisms N- myristoyl transferase (NMT: N-myristoyltransferase, see non-patent document 3.) By translation performed at the same time. Is myristoylation, ribosome during translation in a state of connecting the peptide chain, the N-terminal methionine by methionine N exposed by the removal of α-amino group of glycine, at the amide bonds is myristic acid NMT is caused by the added (see non-patent document 4.). Myristoylation consensus sequence is not present, from the end of the 1 th N Glycine and necessarily, the first 2 amino acids have an electric charge (however, proline, except for the aromatic amine), the first 5 amino acids have an electric charge, is often present in particular serine, and the fourth amino acid except proline 6, the tendency of the filter (see non-patent document 5.).
Proteins involved in intracellular signal transmission system is found in many myristoylation, protein and the cell membrane of reversible due to the interaction with functions. For example, HIV Nef gene product or, myristoylation cancer Src kinase gene product is involved in the functional expression of the protein has been reported (non-patent document 6, the reference 7.). In addition, if the mutations in the N-terminal glycine that fails to become myristoylated protein in the cell membrane and could not be combined, as a result, even when there is no metastatic activity of cancer also are also suggested.
Membrane - protein, or protein - specific interactions between the proteins via, or cellular localization of the protein by performing the activity involved in intracellular signaling and detection of myristoylated proteins, the operation of each one of the cells is important for an understanding of the mechanism of that material (non-patent document 8, the reference 9.).
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • TOKYO INSTITUTE OF TECHNOLOGY
  • Inventor
  • HAYASHI Nobuhiro
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
詳しくお知りになりたい方は下記「問合せ先」まで直接お問合わせください

PAGE TOP

close
close
close
close
close
close